← Back to patent-cliff list
TRQ-001 Triquetra Medicines AB
Tier C — Watch / tradeTRQ-001 Triquetra Medicines AB
Triquetra Medicines AB
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Migraine
Regional status
US
-
EU
Phase II
2024-10-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TRQ-001 Triquetra Medicines AB?
Approved indications include: Migraine.
When does the TRQ-001 Triquetra Medicines AB patent expire?
No public expiry year is available for TRQ-001 Triquetra Medicines AB yet; this page updates once verified.
How do I get a quote for TRQ-001 Triquetra Medicines AB intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01